Cas:5450-31-7 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid manufacturer & supplier

Chemical Name:2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid

CAS.NO:5450-31-7

Synonyms:2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid

Molecular Formula:C₉H₇ClN₂O₂S

Molecular Weight:242.68200

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:504.1ºC at 760 mmHg

Density:1.62g/cm3

Index of Refraction:1.733

PSA:91.28000

Exact Mass:241.99200

LogP:2.39300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid Use and application,2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid technical grade,usp/ep/jp grade.

Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid manufacturer DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid supplier DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 2-[(6-chloro-1H-benzimidazol-2-yl)sulfanyl]acetic acid factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.